From enhancing lesions to brain atrophy in relapsing MS

Journal of Neuroimmunology

Volumn 98, Issue 1, 1999, Pages 7-15

  Simon, Jack H ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Cerebral atrophy; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

BETA INTERFERON;

BRAIN ATROPHY; BRAIN INJURY; CLINICAL TRIAL; CONFERENCE PAPER; DEMYELINATION; DISABILITY; HUMAN; MULTIPLE SCLEROSIS; NERVE INJURY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PRIORITY JOURNAL; RELAPSE;

ATROPHY; BRAIN; CEREBRAL VENTRICLES; DISEASE PROGRESSION; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; TIME FACTORS;

EID: 0033022892     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(99)00075-2     Document Type: Conference Paper

References (37)

1. Barkhof F., Scheltens P., Frequin S.T.F.M.et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs. clinical findings in determining disease activity. AJR. 159:1992;1041-1047.
2. Barnard R.O., Triggs M. Corpus callosum in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 37:1974;1259-1264.
3. Barnes D., Munro P.M.G., Youl B.D., Prineas J.W., McDonald W.I. The long-standing MS lesion: a quantitative MRI and electron microscopic study. Brain. 114:1991;1271-1280.
4. Bruck W., Bitsch A., Kolenda H.et al. Inflammatory central nervous system: correlation of magnetic resonance imaging findings with lesion pathology. Ann. Neurol. 42:1997;783-793.
5. Davie C.A., Barker G.J., Webb S.et al. Persistent function deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain. 118:1995;1583-1592.
6. DeStefano N., Matthews P.M., Antel J.P., Preul M., Francis G., Arnold D.L. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann. Neurol. 38:1995;901-909.
7. Dietemann J.L., Beigelman C., Rumbach L.et al. Multiple sclerosis and corpus callosum atrophy: relationship of MRI findings to clinical data. Neuroradiology. 30:1988;478-480.
8. Estes M.L., Rudick R.A., Barnett G.H., Ransohoff R.M. Stereotactic biopsy of an active multiple sclerosis lesion. immunocytochemical analysis and neuropathologic correlation with magnetic resonance imaging. Arch. Neurol. 47:1990;1299-1303.
9. Filippi M., Campi A., Colombo B.et al. A spinal cord MRI study of benign and secondary progressive multiple sclerosis. J. Neurol. 243(7):1996;502-505.
10. Gass A., Barker G.J., Kidd D.et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann. Neurol. 36:1994;62-67.
11. Huber S.J., Paulson G.W., Shuttleworth E.C.et al. Magnetic resonance imaging correlates of dementia in multiple sclerosis. Arch. Neurol. 44:1987;732-736.
12. IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized,double blind, placebo-controlled trial. Neurology. 43:1993;655-661.
13. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 45:1995;1277-1285.
14. Jacobs L.D., Cookfair D.L., Rudick R.A.et al. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Mult. Scler. 1:1995;118-135.
15. Jacobs L.D., Cookfair D.L., Rudick R.A.et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39:1996;285-294.
16. Johnson K.P., Brooks B.R., Cohen J.A.et al. Copolymer I reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double blind, placebo-controlled trial. Neurology. 45:1995;1268-1276.
17. Katz D., Taubenberger J.K., Cannella B.et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann. Neurol. 34:1993;661-669.
18. Koudriavtseva T., Thompson A.J., Fiorelli M.et al. Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 62:1997;285-287.
19. Loevner L.A., Grossman R.I., McGowan J.C.et al. Characterization of multiple sclerosis plaques with T1-weighted MRI and quantitative magnetization transfer. AJNR. 16:1995;1473-1479.
20. Losseff N.A., Wang L., Lai H.M.et al. Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain. 119:1996;2009-2019.
21. Losseff N.A., Webb S.L., O'Riordan J.I.et al. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain. 119:1996;701-708.
22. McFarland H.F., Frank J.A., Albert P.S.et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann. Neurol. 32(6):1992;758-766.
23. Molyneux P.D., Filippi M., Barkhof F.et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann. Neurol. 43:1998;332-339.
24. Nesbit G.M., Forbes G.S., Scheithauer B.W.et al. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology. 180(2):1991;467-474.
25. Newcombe J., Hawkins C.P., Henderson C.L.et al. Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue. Brain. 114:1991;1013-1023.
26. UBC MS/MRI Study Group and IFNB Multiple Sclerosis Study Group, Paty D.W., Li D.K.B. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI Analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43:1993;662-667.
27. Pelletier J., Habib M., Lyon-Caen O.et al. Functional and magnetic resonance imaging correlates of callosal involvement in multiple sclerosis. Arch. Neurol. 50:1993;1077-1082.
28. Pozzilli C., Bastianello S., Padovani A.et al. Anterior corpus callosum atrophy and verbal fluency in multiple sclerosis. Cortex. 27:1991;441-445.
29. Pozzilli C., Fieschi C., Perani D.et al. Relationship between corpus callosum atrophy and cerebral metabolic asymmetries in multiple sclerosis. J. Neurol. Sci. 11291-112:1992;51-57.
30. Rao S.M., Glatt S., Hammeke T.A.et al. Chronic progressive multiple sclerosis: relationship between cerebral ventricular size and neuropsychological impairment. Arch. Neurol. 42:1985;678-682.
31. Rao S.M., Bernardin L., Leo G.J.et al. Cerebral disconnection in multiple sclerosis: relationship to atrophy of the corpus callosum. Arch. Neurol. 64:1989;918-920.
32. Simon J.H. Contrast enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis. JMRI. 7:1997;29-37.
33. Simon J.H., Schiffer R.B., Rudick R.A., Herndon R.M. Quantitative determination of MS-induced corpus callosum atrophy in vivo by MR imaging. AJNR. 8:1987;599-604.
34. Simon J.H., Jacobs L.D., Campion M. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Ann. Neurol. 43:1998;79-87.
35. Simon, J.H., Jacobs, L., Campion, M. et al., 1999. A longitudinal study of brain atrophy in relapsing MS. Neurology (in press).
36. Trapp B.D., Peterson J., Ransohoff R.M.et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338:1998;278-285.
37. Truyen L., van Waesberghe J.H.T.M., van Walderveen M.A.A.et al. Accumulation of hypointense lesions ('blackholes') on T1 spin echo MRI correlates with disease progression in multiple sclerosis. Neurology. 47:1996;1469-1476.